Ashley Gallagher, MA

Modeling shows PCV20 in pediatric patients prevents millions of pneumococcal cases and saves billions, reshaping vaccination choices for pharmacists and parents.

A large study links an early A1c under 6.5% to fewer eye and nerve complications, urging pharmacists to intensify control and monitor retinopathy.

The FDA expands the drug's usage to treat idiopathic short stature, small for gestational age, and growth failure associated with Noonan syndrome.

Pharmacists can close the gap between recommendations and uptake for pregnant women.

Phase 3 trials show once-daily bictegravir/lenacapavir keeps HIV suppressed after switching regimens, with strong safety and better satisfaction for complex-treatment patients.

Orforglipron beats oral semaglutide in A1C and weight loss in a head-to-head study for type 2 diabetes.

Long-term care pharmacists shift to safety-first care by deprescribing anticholinergics, using dysphagia-friendly forms, and raising vaccination rates.

Three-year QUASAR data show guselkumab keeps most ulcerative colitis patients in remission, with strong healing rates and no new safety issues.

Novo Nordisk’s CagriSema drives 23% weight loss in REDEFINE 4 but misses noninferiority compared with tirzepatide, shaping the next wave of obesity drugs.

The FDA approves Bysanti (milsaperidone) for schizophrenia and bipolar I disorder, leveraging iloperidone bioequivalence, with key metabolic monitoring needs.

New data links glucagon-like peptide-1s to fewer aneurysm ruptures and lower death risk, guiding pharmacists on safer stroke prevention.

Pharmacists lead safer postsurgical pain care, using multimodal nonopioid options and tight opioid stewardship from pre-operation through home.

Pharmacists help explain the complex evidence, address fears around injections and cost, and help patients integrate lifestyle changes alongside pharmacologic therapy for diabetes care.

Community pharmacists strengthen disaster response by coordinating vaccines, bridging care gaps, and securing lifesaving meds under pressure.

Pharmacies expand care with vaccines and birth control services—learn scope, billing tips, and tools to win younger, convenience-driven patients.

Pharmacists help turn Food Is Medicine into covered care, linking heart patients to tailored meals, produce prescriptions, and easier chronic disease prevention.

Duvakitug TL1A antibody sustains remission and endoscopic response for 44 weeks in ulcerative colitis and Crohn disease, supporting phase 3 momentum.

The FDA approves pitolisant for pediatric cataplexy, offering a rare noncontrolled narcolepsy option with real-world safety data and key interaction tips.

Direct contracting can boost transparent drug pricing and help independent pharmacies earn fairly while patients save on generic medications.

The decision removes risk statements regarding cardiovascular disease, breast cancer, and probable dementia from the boxed warning.

As shrinking dispensing margins make it harder for pharmacies to keep their doors open on prescriptions alone, many are turning to clinical services as a lifeline.

GLP-1 therapies lower C-reactive protein and tumor necrosis factor-alpha, signaling cardiovascular protection; pharmacists tackle cost

Phase 3 OCEANIC-STROKE shows asundexian cuts recurrent ischemic stroke by 26% on top of antiplatelets, without more major bleeding.

Pharmacists guide smokers in choosing effective OTC cessation aids, enhancing success rates with tailored nicotine replacement therapies for cravings and withdrawal relief.

Real-world data shows empagliflozin cuts mortality in broader type 2 diabetes patients, supporting wider sodium-glucose co-transporter 2 inhibitor use with careful safety monitoring.

Phase 3 data show oral fenebrutinib slows primary progressive multiple sclerosis disability progression versus ocrelizumab, with early upper-limb gains and a manageable safety profile.

CDC updates vaccination guidelines, emphasizing individual choice for COVID-19 and standalone chickenpox shots, while addressing vaccine hesitancy and misinformation.

TrumpRx drives Most-Favored-Nation drug pricing, cutting US costs for glucagon-like peptide-1, insulin, and fertility medications.

Pharmacists push for provider status and PBM overhaul as IRA policies squeeze pharmacies—what it means for access to vaccines, PrEP, and vital meds.

Pfizer's phase 2b study reveals promising results for its monthly GLP-1 therapy, enhancing weight loss and medication adherence in obesity management.